Contineum Therapeutics, Inc. Class A Common StockCTNMNASDAQ
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank25
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P25
Within normal range
vs 3Y Ago
-2.9x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2025-68.40%
2024-269.75%
2023196.16%
202223.40%
20210.00%